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a b s t r a c t
Gas chromatography coupled to mass spectrometry is the most frequent tool for metabolomic proﬁling
of low molecular weight metabolites. Its suitability in health survey is beyond doubt, given that primary
metabolites involved in central pathways of metabolism are usually altered in diseases. The objective
of this work is to investigate metabolic differences in serum between Alzheimer’s disease patients and
healthy controls in order to elucidatepathologicalmechanismsunderlying todisease. Alterations in levels
of 23 metabolites were detected, including increased lactic acid, -ketoglutarate, isocitric acid, glucose,
oleic acid, adenosine and cholesterol, as well as decreased urea, valine, aspartic acid, pyroglutamate,
glutamine, phenylalanine, asparagine, ornithine, pipecolic acid, histidine, tyrosine, palmitic and uric acid,
tryptophan, stearic acid and cystine. Metabolic pathway analysis revealed the involvement of multiple
affectedpathways, suchas energydeﬁciencies, oxidative stress, hyperammonemia, andothers.Moreover,
it is noteworthy that some of these compounds have not been previously described in AD research, such
as -ketoglutarate, isocitrate pipecolic acid, pyroglutamate and adenosine, conﬁrming the potential of
this metabolomic approach in the search of novel potential markers for early detection of Alzheimer’s
disease.
© 2014 Elsevier B.V. All rights reserved.
22
1. Introduction23
Q2
Metabolomics, based on the analysis of the entire set ofmetabo-24
lites in a tissue or bioﬂuid, provides a comprehensive overview25
of the status of organisms, reﬂecting the interactions between26
genes, proteins and the environment. This integrative approach27
is a perfect tool to understand the biochemical and biological28
mechanisms occurring in complex systems, and for this reason, its29
application is rising in importance in health survey for the study30
Abbreviations: AD, Alzheimer’s disease;HC, healthy control; PCA, principal com-
ponent analysis; PLS-DA, partial least squares discriminant analysis; VIP, variable
importance in the projection.
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of disease pathology, biomarkers discovery and drug development 31
[1]. However, the comprehensive investigation of metabolome is 32
very complicated due to its huge complexity and dynamics, since 33
metabolome represents a vast number of components that belong 34
to awide variety of compound classes, very diverse in their physical 35
and chemical properties, and present in a wide range of concentra- 36
tions [2]. Moreover, metabolite distributions are subjected to high 37
temporal and spatial variability [3]. Thus, there is no single way to 38
performa totalmetabolomic screening, but therearedifferent com- 39
plementary analytical platforms that can be applied, such as NMR 40
[4], FT-IR [5] and mass spectrometry, this latter coupled to separa- 41
tion techniques or using direct infusion mass spectrometry (DIMS) 42
[6]. Among them, gas chromatography coupled to mass spectrom- 43
etry is one of the most frequently used tools for metabolomic 44
proﬁling, especially in plant metabolomics [7], but widespread 45
today to other ﬁelds as biomedical research [8]. Although NMR 46
or DIMS may be preferred techniques for metabolic ﬁngerprint- 47
ing due to high throughput screening capability or minimal sample 48
preparation requirements, GC–MSapproaches present several ana- 49
lytical advantages making it an alternative to consider [9]. First 50
of all, sensitivity is higher than in other conventional techniques 51
employed in metabolomics, and above all, against techniques not 52
http://dx.doi.org/10.1016/j.jpba.2014.10.010
0731-7085/© 2014 Elsevier B.V. All rights reserved.
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based on mass spectrometry. In addition, chromatographic repro-53
ducibility and resolutionexceed thatprovidedbyotherhyphenated54
techniques suchas LC–MSorCE–MS. Finally, it is possible a straight-55
forward identiﬁcation of peaks via libraries of mass spectra, due to56
the highly repeatable mass spectral fragmentation upon electron57
impact ionization [10]. On the other hand, the main downside of58
this technique is that analysis is restricted to volatile metabolites,59
usually after chemical derivatization. For all these reasons, GC–MS60
has been postulated as the technique of choice to get ﬁngerprints61
of low molecular weight metabolites.62
The ability of GC–MS to measure key primary metabolites such63
as amino acids, organic acids or saccharides, involved in essen-64
tial pathways of organisms metabolism, makes it an interesting65
alternative in health survey, particularly in the discovery of dis-66
ease biomarkers. This approach has been previously proposed for67
the study of different pathological situations, such as Parkinson’s68
disease [11], cancer [12,13], diabetes [14], Huntington’s disease69
[15] or Alzheimer’s disease [16]. In this latter case, the discovery70
of biomarkers is of great importance because currently, diagnosis71
of Alzheimer’s disease (AD) is based on the application of clinical72
criteria, since to date no biological markers have been established73
with the required reliability and speciﬁcity [17]. These criteria74
entail signiﬁcant drawbacks, because when patients are diagnosed,75
dementia has already developed and the degree of brain damage is76
widespread. In this sense, the application of GC–MS metabolomics77
can be very useful, since AD is a multifactorial disorder in which78
many cellular processes are deregulated, causing alterations in sev-79
eral families of important low molecular mass metabolites such as80
amino acids [18], fatty acids [19] or neurotransmitters [20]. In this81
study, blood serum samples from AD patients and healthy controls82
were subjected to analysis by GC–MS, and metabolomic proﬁles83
were compared to evaluate the potential of technique for discrimi-84
nation. For this purpose, after chemical derivatization and analysis,85
results were preprocessed for retention time alignment and inten-86
sity normalization, andﬁnallymultivariate analysiswas carried out87
by partial least squares discriminant analysis (PLS-DA), in order to88
identify discriminant metabolites.89
2. Materials and methods90
2.1. Reagents and samples91
Solvents employed were HPLC-grade. Methanol and pyridine92
were purchased from Aldrich (Steinheim, Germany), while ethanol93
was supplied by Merck (Darmstadt, Germany). Water was puri-94
ﬁed with a Milli-Q Gradient system (millipore, Watford, UK).95
Derivatizing agents, methoxylamine hydrochloride and N-methyl-96
N-(trimethylsilyl) triﬂuoroacetamide (MSTFA), were obtained in97
Aldrich. A total of 44 blood serum samples were recruited by98
the Neurological Service of Hospital Juan Ramón Jiménez (Huelva,99
Spain), including healthy controls (HC) and Alzheimer’s disease100
(AD) patients. Alzheimer’s disease patients (n=23, 8 male and 15101
female, medium age 79.2±5.9 y) were newly diagnosed of spo-102
radic AD according to the criteria of the NINCDS-ADRDA [17], and103
only subjects that had not yet received any type of medication104
were included in the study. On the other hand, matched healthy105
controls in sex and age (n=21, 9 male and 12 female, medium106
age 72.1±5.4 y) were enrolled, after examination by neurologists107
to conﬁrm the absence of neurological disorders, whom had not108
more than two reported cases of Alzheimer’s disease in their fami-109
lies. Demographic characteristics of groups considered in the study110
can be found in supplementary material, including age, gender, co-111
morbidities, medication and family history of AD. Most subjects112
suffered other co-morbidities and were under different medical113
treatments, but there were not signiﬁcant differences among AD114
and HC groups. Blood samples were obtained by venipuncture of115
the antecubital region after 8h of fasting and collected in BD Vacu- 116
tainer SST II tubes with gel separator and Advance vacuum system, 117
previously cooled in a refrigerator. The samples were immediately 118
cooledandprotected fromlight for30min toallowclot retraction to 119
obtain serumafter centrifugation (3500 rpm for 10min). The serum 120
was divided into aliquots and frozen at −80 ◦C until analysis. The 121
study was performed in accordance with the principles contained 122
in the Declaration of Helsinki. All persons gave informed consent 123
for the extraction of peripheral venous blood and controls subjects 124
were studiedbyneurologists to conﬁrmtheabsenceof neurological 125
and cognitive disease. 126
2.2. Serum preparation 127
For the extraction of serum metabolites, proteins were pre- 128
cipitated following a modiﬁcation of the procedure described 129
elsewhere [21]: 100L of serum were mixed with 400L of 1:1 130
methanol/ethanol mixture in an Eppendorf tube and vortexed for 131
5min at room temperature, followedby centrifugation at 4000 rpm 132
for 10min at 4 ◦C. The supernatant is transferred to another tube 133
and dried under nitrogen stream. Then, derivatization was car- 134
ried out according to the two step methodology proposed by 135
Begley et al. [22]. For protection of carbonyl groups by methoxy- 136
mation, dried extracts were redissolved in 50L of 20mgmL−1 137
methoxyamine in pyridine, and after brieﬂy vortexing were incu- 138
bated at 80 ◦C for 15min in a water bath. Subsequently silylation 139
was performed by adding 50L of MSTFA and incubation at 80 ◦C 140
for a further 15min. Finally, extracts were centrifuged at 4000 rpm 141
for 5min and supernatant collected for analysis. 142
2.3. GC–MS analysis 143
Chromatographic analysis was performed in a Trace GC ULTRA 144
gas chromatograph coupled to an ion trap mass spectrometer 145
detector ITQ900 (Thermo Fisher Scientiﬁc), using a Factor Four 146
capillary column VF-5MS 30m×0.25mm ID, with 0.25m of ﬁlm 147
thickness (Varian). The GC column temperature was set to 100 ◦C 148
for 0.5min, and programmed to reach 320 ◦C at a rate of 15 ◦C per 149
minute. Finally, this temperature is maintained for other 7min, 150
being the total time of analysis 22.17min. The injector tempera- 151
ture was kept at 280 ◦C, and helium was used as carrier gas at a 152
constant ﬂow rate of 1mlmin−1. For mass spectrometry detection, 153
ionization was carried out by electronic impact (EI) with a volt- 154
age of 70eV, by full scan mode in the m/z range 35–650, with an 155
ion source temperature of 200 ◦C. For analysis, 1l of sample was 156
injected in splitless mode. 157
2.4. Data processing 158
Raw data was processed following the pipeline described by 159
Katajamaa andOresic [23],whichproceeds throughmultiple stages 160
including feature detection, alignment of peaks and normaliza- 161
tion. For this purpose, we employed the freely available software 162
XCMS, included in the R platform (http://www.r-project.org). Files 163
were converted into netCDF using the Thermo File Converter tool 164
(Thermo Fisher Scientiﬁc) and subsequently, data were extracted 165
using the matched ﬁlter method. This algorithm slices data into 166
extracted ion chromatograms (XIC) on a ﬁxed step size, and then 167
each slice is ﬁltered with matched ﬁltration using a second- 168
derivative Gaussian as the model peak shape [24]. The XCMS 169
parameters were optimized according to the characteristics of data 170
sets obtained in order to extract the maximum information as pos- 171
sible. Finally, the settings applied for were S/N threshold 2, full 172
width at half-maximum (fwhm) 3, and width of the m/z range 0.1 173
(step parameter). After peak extraction, grouping and retention 174
time correction of peaks (alignment) was accomplished in three 175
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Fig. 1. GC/MS chromatograms from (a) Alzheimer’s disease and (b) healthy control samples.Q5
iterative cycles with descending bandwidth (bw) from 5 to 1 s.176
Then, imputation of missing values was performed by returning177
to the raw spectral data and integrating the areas of the missing178
peaks which are below the applied signal-to-noise ratio threshold,179
using the ﬁllPeaks algorithm. For data normalization, the locally180
weighted scatter plot smoothing (LOESS) normalization method181
was used, which adjusts the local median of log fold changes of182
peak intensities between samples in the data set to be approxi-183
mately zero across thewholepeak intensity range [25]. Finally, data184
were submitted to logarithmic transformation, in order to stabilize185
the variance of results. The preprocessed data were then exported186
as a .csv ﬁle for further data analysis by multivariate procedures.187
2.5. Data analysis188
Results were subjected to multivariate analysis by principal189
component analysis (PCA) and partial least squares discriminant190
analysis (PLS-DA) in order to compare metabolomic proﬁles 191
obtained, using the SIMCA-PTM software (version 11.5, published 192
byUMetrics AB, Umeå, Sweden). Before performing statistical anal- 193
ysis, data was submitted to Pareto scaling, for reducing the relative 194
importance of larger values, and logarithmic transformation, in 195
order to approximate a normal distribution [26]. Performance of 196
models was assessed by the R2 and Q2 values, provided by the soft- 197
ware (indicative of class separation and predictive power of the 198
model, respectively). Finally, metabolites responsible for discrim- 199
ination were selected according to the Variable Importance in the 200
Projection, or VIP (a weighted sum of squares of the PLS weight, 201
which indicates the importance of the variable in the model), con- 202
sidering only variables with VIP values higher than 1.5, indicative 203
of signiﬁcant differences among groups. These potential markers 204
were identiﬁed using the NIST Mass Spectral Library (version 08), 205
considering only those variables with a similarity index (SI) greater 206
than 70%. 207
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Fig. 2. Scores plots of PCA (a) and PLS-DA (b)models for GC–MS data. Black squares:Q6
AD patients; red circles: HC, healthy controls. (For interpretation of the references
to color in ﬁgure legend, the reader is referred to the web version of the article.)
2.6. Metabolic pathway analysis208
Metabolic pathway analysis was subsequently performed to209
identify and visualize the affected pathways on the basis of poten-210
tial biomarkers detected. For this purpose, the MetPA web tool211
was employed (http://metpa.metabolomics.ca), which conducts212
pathway analysis through pathway enrichment analysis and path-213
way topological analysis [27]. In this work, we select the Homo214
sapiens library and use the default ‘Hypergeometric Test’ and215
‘Relative-Betweenness Centrality’ algorithms for pathway enrich-216
ment analysis and pathway topological analysis, respectively. In217
order to identify the most relevant pathways, the impact-value218
threshold calculated from pathway topology analysis was set to219
0.1.220
3. Results221
Serum metabolomic proﬁles obtained by GC–MS (Fig. 1) were222
submitted to multivariate statistical analysis in order to evalu-223
ate the potential of the methodology to discriminate between224
AD patients and healthy control subjects. Thus, after raw data225
pre-processing, Pareto scaling and logarithmic transformation,226
principal component analysis (PCA) was applied to check trends,227
outliers, and quality of the analysis. This unsupervised method was228
not able to discriminate between groups (Fig. 2a), but showed a229
clustering of samples in the scores plot without signiﬁcant out-230
liers according to the Hotelling T2-range plot. Then, partial least231
squares discriminant analysis (PLS-DA) was used in the same data232
set to build a predictive model for classiﬁcation of samples. PLS-233
DA scores plots (Fig. 2b) displayed a clear separation between AD234
patients and controls, being obtained good class separation value235
and predictive power in a three components model (with R2 =0.99236
and Q2 =0.74). Metabolites responsible for discrimination were237
Table 1
Potential biomarkers of AD identiﬁed by GC–MS metabolic proﬁling. Q7
RT (min) Metabolite Fold change
Decreased metabolites
5.18 Valine 0.87
5.58 Urea 0.56
7.78 Aspartic acid 0.86
8.00 Pyroglutamic acid 0.85
8.63 Glutamine 0.82
8.87 Phenylalanine 0.72
9.08 Asparagine 0.85
10.20 Ornithine 0.76
10.97 Pipecolic acid 0.75
11.05 Histidine 0.83
11.13 Tyrosine 0.86
11.90 Palmitic acid 0.65
12.17 Uric acid 0.71
13.07 Tryptophan 0.73
13.17 Stearic acid 0.78
13.42 Cystine 0.88
Increased metabolites
4.00 Lactic acid 1.51
8.30 -Ketoglutarate 1.33
10.15 Isocitric acid 1.53
10.75 Glucose 1.92
13.02 Oleic acid 1.28
15.42 Adenosine 1.31
20.00 Cholesterol 1.90
then selected according to the variable importance in the projec- 238
tion (VIP >1.5), indicative of signiﬁcant differences among groups 239
(Table 1). Subsequently, altered biochemical pathways associated 240
with these abnormalities were identiﬁed by metabolic pathway 241
analysis. An overview of this analysis is shown in Fig. 3, where 242
eachnode represents ametabolic pathway and its size indicates the 243
impact of this pathway in response to Alzheimer’s disease, reveal- 244
ing important impairments in energymetabolism and homeostasis 245
of amino acids. 246
4. Discussion 247
In a recent work, we demonstrated that serum metabolomics 248
using ﬂow injection analysis with atmospheric pressure 249
Fig. 3. Pathway analysis overview showing altered metabolic pathways in serum
from AD patients. (a) Alanine, aspartate and glutamate metabolism; (b) arginine
and proline metabolism; (c) TCA cycle; (d) histidine metabolism; (e) pyruvate
metabolism; (f) phenylalanine metabolism; (g) tryptophan metabolism.
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photoionization mass spectrometry (FIA-APPI-MS) may be250
very useful for the study of pathological mechanisms associated251
with Alzheimer’s disease, showing the involvement of numerous252
non-polar compounds (principally lipids) [28]. However, ﬁndings253
presented here highlight the potential of complementary GC–MS254
analysis for the comprehensive assessment of serum metabolome,255
demonstrating the implication of low molecular weight metabo-256
lites in the pathogenesis of this disorder. As shown in Table 1, the257
levels of 23 metabolites are signiﬁcantly altered in AD patients258
compared with healthy controls: lactic acid, -ketoglutarate, isoc-259
itric acid, glucose, oleic acid, adenosine and cholesterol increased260
in AD patients, while urea, valine, aspartic acid, pyroglutamate,261
glutamine, phenylalanine, asparagine, ornithine, pipecolic acid,262
histidine, tyrosine, palmitic and uric acid, tryptophan, stearic acid263
and cystine decreased in these samples. These metabolic differ-264
ences in serum could be related to different perturbed cellular265
pathways (Fig. 3), and therefore it is possible to understand the266
biochemical processes underlying the pathology.267
One of the most important changes observed in this study is the268
associated with an abnormal energy metabolism, corroborated by269
the increased levels of glucose, lactic acid,-ketoglutarate and isoc-270
itrate in AD samples, and complementary decrease of aspartate and271
asparagine. Depletion in neuronal energy production by decreased272
rate of carbohydrate catabolism has been repeatedly documented273
in Alzheimer’s disease [29], which is consistent with the increase274
found for serum levels of glucose (Table 1). In addition, this per-275
turbed use of glucose by the neuron is also reﬂected in increased276
serum lactate, previously reported in CSF samples fromADpatients277
in association with higher pyruvate levels [30]. On the other hand,278
this bioenergetic deﬁciency is also characterized by a dysfunc-279
tion in mitochondrial activities [31]. In this sense, impairments280
in enzymes involved in tricarboxylic acid (TCA) cycle have been281
previously reported, with signiﬁcant decreases in the activities of282
pyruvate dehydrogenase complex, isocitrate dehydrogenase, and283
-ketoglutarate dehydrogenase complex, and increased activities284
of succinate dehydrogenase (complex II) and malate dehydroge-285
nase in AD patients [32]. Furthermore, alterations in the levels of286
TCA intermediates or related compounds have also been described287
[33]. Thus, although to date it has not been previously reported an288
increase of -ketoglutarate and isocitrate in AD serum samples,289
this situation is in complete agreement with the reduced activ-290
ities of corresponding enzymes, -ketoglutarate dehydrogenase291
and isocitrate dehydrogenase respectively, representing a possible292
new marker of aberrant energy metabolism in Alzheimer’s dis-293
ease. Finally, reduced serum levels were found for the amino acids294
aspartate, produced fromoxalacetate, and itsderivativeasparagine.295
Nevertheless, contradictory results may be found with respect to296
this point in literature, considering plasma, cerebrospinal ﬂuid and297
brain samples [34–36], so no clear conclusions can be drawn. Tak-298
ing all these facts into account,we can conclude thatmechanismsof299
energyproductionare completelyperturbed inAD, affectingglycol-300
ysis, TCA cycle or synthesis of related amino acids, as schematized301
in Fig. 4.302
Adenosine was other important metabolite contributing to the303
metabolomic differentiation of AD andHC samples. This nucleoside304
acts as neuromodulator andneuroprotector, controlling the release305
of glutamate [37]. It has been reported the up-regulation of adeno-306
sine receptors in the frontal cortex of AD patients [38], as well as307
the redistribution of these receptors, with a higher activity in neu-308
rons affected by  amyloid deposition or hyperphosphorilation of309
 protein [39]. Thus, although high adenosine levels in brain have310
been related with normal ageing process [40], our experimental311
results indicate that an extra increase is produced in AD patients.312
Other discriminant metabolites found in GC–MS proﬁles related313
to the neurotransmitter system are the amino acids tryptophan,314
tyrosine, phenylalanine and glutamine, all of them decreased in AD315
Fig. 4. Altered energy metabolism in AD. (↑) increased metabolites in AD samples;
(↓) decreased metabolites in AD samples.
sera. Tryptophan is directly involved in two important pathways 316
closely related to Alzheimer’s disease, such as kynurenine path- 317
way [41] and serotonergic system [42], and reduction of this amino 318
acid in blood and cerebrospinal ﬂuid of AD patients is well known 319
[43,44]. On the other hand, phenylalanine and tyrosine partici- 320
pate in catecholaminemetabolism for dopamine synthesis, and it is 321
also well documented their decrease in serum, cerebrospinal ﬂuid 322
and brain from AD patients [18,34,35]. Finally, reduced glutamate 323
neurotransmission is other characteristic hallmark of Alzheimer’s 324
disease [45], leading to low levels of corresponding neurotransmit- 325
ters glutamate and glutamine (Table 1). 326
Several lipids also contributed for discriminating AD patients 327
and healthy volunteers, including free fatty acids (increased oleic 328
acid, and decreased palmitic and stearic acids in AD) or cholesterol. 329
Fatty acids are bioactive molecules contributing to cell structure, 330
energy storage and signal transduction, present at very high lev- 331
els in neurons (50% of the neuronal membrane is composed by 332
polyunsaturated fatty acids). An increasing number of studies 333
have reported the potential relationship between fatty acids and 334
Alzheimer’s disease, and numerous works have demonstrated that 335
long-chain n-3 fatty acids are inversely correlated with the devel- 336
opment ofAlzheimer’s disease [46].Moreover, has been shown that 337
high levels of free fatty acids induce the amyloid deposition and 338
tau hyperphosphorilation, contributing to the pathogenesis of AD 339
[47]. However, previous works focused on analysis of fatty acids in 340
brain, serum or plasma from Alzheimer’s disease patients provided 341
contradictory results [19,48,49]. Thus, the interpretation of altered 342
levels of oleic, palmitic and stearic acids requires some caution, and 343
probably further research is needed to establish accurate conclu- 344
sions about the role of these compounds in AD development. On 345
the other hand, the relationship between levels of cholesterol and 346
AD progression is much more evident, since the increase of total 347
cholesterol content in brain tissue has been correlated with the 348
deposition of amyloid beta [50]. This situation of hyperlipidemia 349
can affect to cerebrovascular system, leading decreased cerebral 350
blood ﬂow and ﬁnally, neuronal cell loss [51]. 351
Ornithine and urea are two metabolites involved in urea 352
cycle, responsible for nitrogen reutilization in conjunction with 353
guanidine cycle [52], and controlling ammonia concentrations. 354
Deﬁciencies in urea cycle may result in hyperammonemia, with 355
deleterious effects on central nervous system [53]. In this sense, 356
the role of this cycle in AD has been discussed, and was found 357
that the expression of related genes is altered [54]. Therefore, 358
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the decrease in these two metabolites (Table 1) could be con-359
sistent with impaired nitrogen metabolism. Moreover, reduced360
ornithine levels could also be related with a perturbed status of361
polyamine system, given that overexpression of ornithine decar-362
boxylase, responsible for the transformation of precursor ornithine363
in putrescine, is a common feature in AD [55].364
It can also be noted that concentration of pyroglutamate365
decreases in AD serum, indicating the deregulation of the -366
glutamyl cycle (GGC). The main function of GGC is the transport367
of amino acids across the blood brain barrier by facilitative trans-368
port system L1, which may allow both desirable and undesirable369
amino acids to enter the brain by means of a carrier molecule of370
glutathione [56]. In this process a molecule of pyroglutamate is371
released,which is essential since stimulates sodiumdependent car-372
riers for the later removal of deleterious amino acids from brain.373
Thus, this cycle has a great importance in the regulation of cere-374
bral glutamate, toxic to the brain at very low concentrations [57].375
Changes in this cycle are known in AD brain, including decreases376
of the GSH/GSSG ratio, diminished -glutamylcysteine synthetase377
activity in de novo glutathione synthesis and increased activity378
of enzymes related to the GSH use such as glutathione perox-379
idase, -glutamyl transpeptidase, and glutathione S-transferase380
[58]. However, to our knowledge, is the ﬁrst time that decreased381
concentration of pyroglutamate in serum is associated with AD.382
The consequences of oxidative stress are especially important in383
neurodegenerative diseases, since brain is particularly susceptible384
to reactive oxygen species, which can attack neuronal lipids, pro-385
teins and nucleic acids, inevitably leading to neuronal dysfunction386
[59]. This pathological status is conﬁrmed in metabolomic proﬁles387
by the reduction of three important compounds involved in the388
protection against oxidative stress: uric acid, cystine and histidine.389
Uric acid is one of the most common systemic plasma antioxi-390
dants, and its reduction in oxidative situations as AD has been391
previously reported [60]. On the other hand, cystine is the major392
form of cysteine at physiological conditions, being the limiting fac-393
tor in the biosynthesis of glutathione. Reduced glutathione is the394
most important antioxidant for the defense of brain cells against395
oxidative stress and excitotoxicity of glutamate, and its deﬁcit is396
associated to different disorders as AD [61]. Finally, histidine is an397
amino acidwith antioxidant properties as other imidazole contain-398
ing compounds such as carnosine or anserine, whose reduction has399
been previously related to AD [34].400
Pipecolic acid is a degradation product of lysine in cere-401
bral peroxisomes, which can act as neurotransmitter modulating402
GABAergic transmission, so that altered levels of this metabolite403
might be indicative of peroxisomal disease. The relation of this dis-404
orderwithAlzheimer’s diseasehasbeenpreviouslydescribed, since405
these organelles are responsible for the biosynthesis of docosahex-406
aenic acid [62] and plasmalogens [63], both reduced in AD patients.407
Therefore, decrease of serumpipecolate levels can be considered as408
a new unequivocally marker of peroxisomal failure. Finally, valine409
was also reduced in serumsamples fromADpatients, in accordance410
with previous results in other neurodegenerative disorder as Hunt-411
ington’s disease [15]. Valine deﬁciency is related to neurological412
defects in rats [64], but its relation with AD is not clear.413
5. Conclusions414
The involvement of several low molecular weight metabo-415
lites in Alzheimer’s disease has been found in the basis of the416
deregulation of numerous cellular processes, demonstrating the417
suitability of gas chromatography coupled to mass spectrometry418
for the elucidation of underlying pathological mechanisms. Selec-419
tion of optimal experimental conditions for sample preparation,420
chromatographic analysis and data treatment allowed obtaining421
comprehensive metabolomic proﬁles of serum samples, useful for 422
the discrimination of ADpatients fromhealthy controls. Thus, up to 423
23 potential biomarkers were identiﬁed, which were related to dif- 424
ferent impairments associated with AD, such as hypometabolism, 425
oxidative stress, changes in neurotransmission system, and others. 426
Many of them have not been previously described (pipecolic acid, 427
pyroglutamate, adenosine,-ketoglutarate, isocitrate), so our ﬁnd- 428
ings provide a ﬁrst step for the development of novel markers for 429
early detection of Alzheimer’s disease. 430
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